Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
Lumos Pharma (NASDAQ:LUMO) will report its full year 2020 financial results on March 9, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. Investors can access the live audio via a provided link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 under evaluation for Pediatric Growth Hormone Deficiency in a Phase 2b trial. The company has received Orphan Drug Designation for LUM-201 in both the US and EU.
- Lumos Pharma's lead candidate LUM-201 received Orphan Drug Designation in the US and EU.
- LUM-201 is currently in a Phase 2b clinical trial for Pediatric Growth Hormone Deficiency.
- None.
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2020 financial results after market close on Tuesday, March 9, 2021. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) or through the link, https://edge.media-server.com/mmc/p/6ujteayr. The link to the live webcast may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available for two weeks from the date of the call and may be accessed through the same link above or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode: 3735869.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When will Lumos Pharma report its financial results for 2020?
What is the focus of Lumos Pharma's lead candidate LUM-201?
At what time is the Lumos Pharma conference call scheduled?
What kind of drug is LUM-201?
